hasan shokri

and 2 more

Introduction: SLE is a chronic autoimmune rheumatic disease that is caused by autoantibodies and immune complexes for unknown reasons and causes damage to cells and organs. The aim of this study was to evaluate the association of ANA panel antibody with clinical manifestations in patients with SLE Methods: This retrospective cross-sectional study was performed on 110 patients with SLE. Clinical manifestations were evaluated according to ACR and SLICC criteria. In serum, the surface of ANA Profilling antibody was examined Results: There was no significant relationship between ANA profiling tests and disease manifestations. Except for the Anti-Ds DNA test, which was significantly associated with the clinical manifestations. (P <0.05). The results obtained from the logistic regression model show that none of these variables age, sex, malar rash, discoid, oral ulcer, nephritis and arthritis have a significant effect on the outcome Anti-U1RNP / Sm (RNP / Sm), Anti-RO- 52 recombinants, Anti-La / SS, Anti-SM not available (P > 0.05) Only age at onset has a significant effect on Anti SSA-Ro 60 (SSA) and Anti-Ds DNA tests. That is, on average, for each year of increasing the duration of the disease, the chance of a positive chance is about and about 16% increases for both tests. No significant correlation was observed with other test results at baseline. Conclusion: The present study shows an increase in the age of onset of the disease and also a decrease in the percentage of renal disorders compared to the study of the previous two decades in Iran.

Maryam Mahdifar

and 5 more

Abstract Background and Purpose: Galbanic acid (GBA), a sesquiterpene coumarin compound isolated from Ferula species, has noticeable anti-cancer effects. In current research, we investigated effects of GBA in combination with arsenic trioxide (ATO) on MT-2 cells, an Adult T cell leukemia (ATL) cell line. ATL is a malignancy caused by human T cell leukemia virus type 1 (HTLV-1). Experimental Approach: The MT-2 cells were treated with each agent alone at various concentrations. After determination of IC50 values, MT-2 cells were treated with 20 µM GBA combined with 4 µM ATO. The viability of MT-2 cells was evaluated by alamar blue assay and cell cycle distribution was assessed by PI staining. Furthermore, the activity of P-glycoprotein (P-gp) in the presence of GBA was studied by mitoxantrone efflux assay. To understand the molecular mechanisms of GBA+ATO treatment in MT-2 cells, the mRNA expression of RelA, p53, CDK4, c-MYC, c-FLIPL, and c-FLIPS was measured by real-time PCR. Key Results: GBA+ATO synergistically inhibited proliferation of MT-2 cells and induced apoptotic cell death. GBA and ATO also synergized to induce cell cycle arrest with an apparent sub-G1 cells accumulation. Rate of mitoxantrone accumulation in MT-2 cells was enhanced in the presence of GBA, indicating GBA has inhibitory effects on the functionality of the P-gp efflux pump. The real-time PCR analysis revealed that GBA+ATO combination downregulated the expression of p53, CDK4, c-FLIPL, and c-FLIPS. Statistical analysis revealed a significant relation between p53 expression and c-FLIPS. Conclusion and Implications: The GBA+ATO combination could be considered as a new therapeutic approach for ATL patients.